Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2021 Sep 27;21(1):1014.
doi: 10.1186/s12879-021-06451-7.

Usefulness of convalescent plasma transfusion for the treatment of severely ill COVID-19 patients in Pakistan

Tehmina Nafees Sonia Khan  1 , Samina Naz Mukry  2 , Shahtaj Masood  3 , Lubna Meraj  4 , Bikha Ram Devrajani  5 , Javed Akram  6 , Naveena Fatima  2 , Sidra Maqsood  2   7 , Ayesha Mahesar  8 , Roomana Siddiqui  9 , Sadia Ishaque  10 , Muhammad Bilal Afzal  11 , Sanam Mukhtar  12 , Sara Ahmed  13 , Arshi Naz  2 , Tahir Sultan Shamsi  2
Affiliations
Clinical Trial

Usefulness of convalescent plasma transfusion for the treatment of severely ill COVID-19 patients in Pakistan

Tehmina Nafees Sonia Khan et al. BMC Infect Dis. .

Abstract

Background: Convalescent plasma(CP) was utilized as potential therapy during COVID-19 pandemic in Pakistan. The study aimed at appraisal of CP transfusion safety and usefulness in COVID pneumonia.

Methods: Single arm, MEURI study design of non-randomized open label trial was conducted in five centers. Patients werecategorized as moderately severe, severe, and critical. The primary endpoint was a) improvement in clinical status and change in category of disease severity; secondary endpoint was b) CP ability to halt disease progression to invasive ventilation. CP transfused to hospitalized patients. Statistical tests including median (interquartile ranges), Mann-Whitney U test, Fisher's exact test using SPSS ver. 23, ANOVA and Chi-square test were applied for the analysis of results parameters before and after CP treatment. SOFA score was applied for multiorgan failure in severe and critical cases.

Results: A total of 50 adult patients; median age 58.5 years (range: 29-92 years) received CP with infusion titers; median 1:320 U/mL (Interquartile range 1:80-1:320) between April 4 to May 5, 2020. The median time from onset of symptoms to enrollment in trial was 3 to 7 days with shortness of breath and lung infiltration as severity criterion. In 35 (70%) recipients, oxygen saturation improved from 80 to 95% within 72h, with resolution of lung infiltrates. Primary endpoint was achieved in 44 (88%) recipients whereas secondary endpoint was achieved in 42 (84%). No patient experienced severe adverse events. A high SOFA score (> 7) correlated with deaths in severe and critical patients. Eight (16%) patients expired due to comorbidities; cardiac arrest in 2 (4%), multiorgan failure secondary to cytokine storm in 5 (10%) and ventilator associated complications in 1 (2%).

Conclusion: CP transfusion can be used as a safe and useful treatment in moderately severe and severe patients.

Trial registration: The trial registration number is NCT04352751 ( https://www.irct.ir/search/result?query=IRCT20200414047072N1 ). Trial Registration date is 28th April 2020.

Keywords: COVID-19; Convalescent CP recipient; Convalescent plasma (CP); SARS CoV2 infection; SOFA score.

PubMed Disclaimer

Conflict of interest statement

There are no conflict of interest to disclose.

Figures

Fig. 1
Fig. 1
The country plan for Passive immunization explains the entire process from submission of protocol for approval to site management, data sharing and monitoring of entire trial process in all authorized centers of transfusion across Pakistan
Fig. 2
Fig. 2
Manifests the initial response as decline in raised values of Respiratory rate, CRP, ferritin, and increased Oxygen saturation after CP administration in first 72 h
Fig. 3
Fig. 3
Radiological findings on chest X-ray of COVID-19 positive patient. A Pre-CP findings exhibits patchy infiltrations bilaterally. B Post CP CXR shows absorption of pulmonary infiltrates and improvement bilaterally on 5th day of CP transfusion
Fig. 4
Fig. 4
Survival curve of moderate, severe, and critical COVID-19 CP recipient patients through Kaplan-Meier analysis
See this image and copyright information in PMC

References

    1. Siddell SG. The coronaviridae. Springer. 1995:1–10. https://www.springer.com/gp/book/9780306449727.
    1. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N, Bi Y, Ma X, Zhan F, Wang L, Hu T, Zhou H, Hu Z, Zhou W, Zhao L, Chen J, Meng Y, Wang J, Lin Y, Yuan J, Xie Z, Ma J, Liu WJ, Wang D, Xu W, Holmes EC, Gao GF, Wu G, Chen W, Shi W, Tan W. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565–574. doi: 10.1016/S0140-6736(20)30251-8. - DOI - PMC - PubMed
    1. Ali I, Alharbi OML. COVID-19: Disease, management, treatment, and social impact. Sci Total Environ. 2020;728:138861. 10.1016/j.scitotenv.2020.138861. Epub 2020 Apr 22. - PMC - PubMed
    1. Zhu Z, Lu Z, Xu T, Chen C, Yang G, Zha T, Lu J, Xue Y. Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19. J Infect. 2020;81(1):e21–ee3. doi: 10.1016/j.jinf.2020.03.060. - DOI - PMC - PubMed
    1. Wooding DJ, Bach H. Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks. Clin Microbiol Infect. 2020;26(10):1436–1446. doi: 10.1016/j.cmi.2020.08.005. - DOI - PMC - PubMed

Publication types

Associated data